(Total Views: 491)
Posted On: 08/31/2018 8:42:24 AM
Post# of 30034
Re: investorxc #27082
I share your frustration, but I am sure the company is trying hard to get that first fundamental investment. The bottom line is someone will be lucky enough to be the first money in and the tremendous upside associated with it. As AMBS makes progress and get closer to the Elto/ESS clinic and LymPro data, there are fewer and fewer reasons to say no. As soon as someone takes the plunge, others will rush in.
The reason for lack of willing investors is mostly due to risk of current debt obligation. One way to mitigate this is if each sub documents its assets, liabilities and equity on its own balance sheet rather than on the parent company’s balance sheet.
I believe that is why they are focusing on the subsidiaries. The article of amendment for Elto Pharma possible is part of such plan. I am sure the other subs will follow suit. All they need now is a willing partner.
The reason for lack of willing investors is mostly due to risk of current debt obligation. One way to mitigate this is if each sub documents its assets, liabilities and equity on its own balance sheet rather than on the parent company’s balance sheet.
I believe that is why they are focusing on the subsidiaries. The article of amendment for Elto Pharma possible is part of such plan. I am sure the other subs will follow suit. All they need now is a willing partner.
(3)
(0)Scroll down for more posts ▼
